Cellares

South San Francisco, CA
Platform Provider
CAR-T Cell Therapy
Program data pending ClinicalTrials.gov matching · Last scored 2026-03-15
66.3
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (20)

Quick Facts: Cellares

Signal Score
66.3/100 (as of 2026-03-15)
Quality Compliance
Assessment pending
Headquarters
South San Francisco, CA
Modalities
CAR-T, Cell Therapy
Active CGT Programs
No ClinicalTrials.gov matches confirmed — 1 partnership announcement in press
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CGT manufacturing intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations 65.2
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Source: ClinicalTrials.gov
No clinical trial matches found for this manufacturer · Operational score requires ClinicalTrials.gov data
Programs — no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 63.0
Active fundraising/financial news (5 articles)
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Active fundraising/financial news (5 articles)
Capacity 71.0
Active facility expansion (2 articles)
Regulatory milestones (5 articles)
Sites: South San Francisco, CA
Source: SEC EDGAR, press monitoring, company profiles
1 CGT manufacturing site
StatusAvailable
Active facility expansion (2 articles)
Regulatory milestones (5 articles)
Sites: South San Francisco, CA
Recent Press20 articles
Active facility expansion (2 articles)
Regulatory milestones (5 articles)

Recent News 20 articles

general 2026-02-25
Cell Therapy Works. The Facility Doesn’t. Cellares Is Redesigning the Infrastructure. - geneonline.com
Cell Therapy Works. The Facility Doesn’t. Cellares Is Redesigning the Infrastructure.  geneonline.com
Source →
general 2026-02-23
Cellares Secures $257M to Scale Automated Cell Therapy Manufacturing - The Healthcare Technology Report.
Cellares Secures $257M to Scale Automated Cell Therapy Manufacturing  The Healthcare Technology Report.
Source →
partnership 2026-02-18
Cellares and University of Wisconsin School of Medicine and Public Health Expand Partnership to Clinical Manufacturing of CRISPR-Edited CAR-T for Solid Tumors - Business Wire
Cellares and University of Wisconsin School of Medicine and Public Health Expand Partnership to Clinical Manufacturing of CRISPR-Edited CAR-T for Solid Tumors  Business Wire
Source →
general 2026-02-10
Cellares to expand automated manufacturing to gene-edited stem cell therapies - MSN
Cellares to expand automated manufacturing to gene-edited stem cell therapies  MSN
Source →
general 2026-02-08
Cellares to expand automated manufacturing to gene-edited stem cell therapies - News-Medical
Cellares to expand automated manufacturing to gene-edited stem cell therapies  News-Medical
Source →
financial 2026-02-04
Cellares Secures $257 Million Series D to Revolutionize Cell Therapy Manufacturing - SynBioBeta
Cellares Secures $257 Million Series D to Revolutionize Cell Therapy Manufacturing  SynBioBeta
Source →
general 2026-02-03
Cellares to Expand Automated Manufacturing to Gene-Edited Stem Cell Therapies - Business Wire
Cellares to Expand Automated Manufacturing to Gene-Edited Stem Cell Therapies  Business Wire
Source →
general 2026-02-03
Cellares Scales IDMO Model for Gene-Edited Stem Cell Therapies - PharmTech.com
Cellares Scales IDMO Model for Gene-Edited Stem Cell Therapies  PharmTech.com
Source →
general 2026-02-03
Cellares to Expand Automated Manufacturing to Gene-Edited Stem Cell Therapies - The Chronicle-Journal
Cellares to Expand Automated Manufacturing to Gene-Edited Stem Cell Therapies  The Chronicle-Journal
Source →
general 2026-01-30
Cellares hits $600m investment milestone to scale automated smart factories - BioProcess International
Cellares hits $600m investment milestone to scale automated smart factories  BioProcess International
Source →
general 2026-01-29
Cellares Secures $257M to Scale Global Cell Therapy Manufacturing - PharmTech.com
Cellares Secures $257M to Scale Global Cell Therapy Manufacturing  PharmTech.com
Source →
financial 2026-01-29
Cellares Raises $257M Series D to Take Cell Therapy Manufacturing Global Ahead of Commercial Launch - HLTH
Cellares Raises $257M Series D to Take Cell Therapy Manufacturing Global Ahead of Commercial Launch  HLTH
Source →
regulatory 2026-01-29
Industrial-Scale Cell Therapy Automation Gains Traction with New Cellares Funding - BioPharm International
Industrial-Scale Cell Therapy Automation Gains Traction with New Cellares Funding  BioPharm International
Source →
general 2026-01-29
Cellares raises $257M to scale automated cell therapy - NJBIZ
Cellares raises $257M to scale automated cell therapy  NJBIZ
Source →
financial 2026-01-29
Cellares: $257 Million Series D Closed To Scale Automated Cell Therapy Manufacturing - Pulse 2.0
Cellares: $257 Million Series D Closed To Scale Automated Cell Therapy Manufacturing  Pulse 2.0
Source →
financial 2026-01-28
Cellares' series D round draws $257M as cell therapy contractor takes operations global - Fierce Pharma
Cellares' series D round draws $257M as cell therapy contractor takes operations global  Fierce Pharma
Source →
financial 2026-01-28
Cellares raises $257M Series D to automate cell therapy manufacturing - drugdiscoverytrends.com
Cellares raises $257M Series D to automate cell therapy manufacturing  drugdiscoverytrends.com
Source →
facility_expansion 2026-01-28
BMS-Partnered Cellares Raises $257M for Cell Therapy Manufacturing Expansion - BioSpace
BMS-Partnered Cellares Raises $257M for Cell Therapy Manufacturing Expansion  BioSpace
Source →
regulatory 2026-01-28
Cellares Raises $257M to Industrialize Global Cell Therapy Manufacturing - Contract Pharma
Cellares Raises $257M to Industrialize Global Cell Therapy Manufacturing  Contract Pharma
Source →
regulatory 2026-01-28
Cellares Raises $257 Million Series D Led by BlackRock and Eclipse to Industrialize Global Cell Therapy Manufacturing with Breakthrough Automation - Business Wire
Cellares Raises $257 Million Series D Led by BlackRock and Eclipse to Industrialize Global Cell Therapy Manufacturing with Breakthrough Automation  Business Wire
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Cell Therapy CDMOs →